Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Cash (2023 - 2025)

Historic Change in Cash for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $30.5 million.

  • CG Oncology's Change in Cash rose 6721.09% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 9476.73%. This contributed to the annual value of $248.8 million for FY2024, which is 41148.14% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Change in Cash is $30.5 million, which was up 6721.09% from -$26.8 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Change in Cash registered a high of $213.7 million during Q4 2024, and its lowest value of -$215.6 million during Q1 2025.
  • Its 3-year average for Change in Cash is -$3.9 million, with a median of -$2.0 million in 2023.
  • Its Change in Cash has fluctuated over the past 5 years, first skyrocketed by 1074559.04% in 2024, then crashed by 41154.59% in 2025.
  • CG Oncology's Change in Cash (Quarter) stood at -$2.0 million in 2023, then skyrocketed by 10745.59% to $213.7 million in 2024, then tumbled by 85.71% to $30.5 million in 2025.
  • Its Change in Cash stands at $30.5 million for Q3 2025, versus -$26.8 million for Q2 2025 and -$215.6 million for Q1 2025.